Opin vísindi

Circulating N-formylmethionine and metabolic shift in critical illness : a multicohort metabolomics study

Circulating N-formylmethionine and metabolic shift in critical illness : a multicohort metabolomics study

Title: Circulating N-formylmethionine and metabolic shift in critical illness : a multicohort metabolomics study
Author: Sigurðsson, Martin Ingi
Kobayashi, Hirotada
Amrein, Karin
Nakahira, Kiichi
Rogers, Angela J.
Pinilla-Vera, Mayra
Baron, Rebecca M.
Fredenburgh, Laura E.
Lasky-Su, Jessica A.
Christopher, Kenneth B.
Date: 2022-10-19
Language: English
Scope: 1632266
University/Institute: Landspitali - The National University Hospital of Iceland
Department: Perioperative Services
Faculty of Medicine
Series: Critical Care; 26(1)
ISSN: 1364-8535
DOI: 10.1186/s13054-022-04174-y
Subject: Svæfinga- og gjörgæslulæknisfræði; Acylcarnitine; Branched chain amino acids; Critical illness; Metabolic shift; Metabolomics; N-formylmethionine; Pentose phosphate pathway; Intensive Care Units; Fatty Acids; Hospital Mortality; Humans; Critical Illness; Clinical Trials as Topic; Amino Acids, Branched-Chain; Kynurenine; Adult; Female; N-Formylmethionine; Metabolomics/methods; Critical Care and Intensive Care Medicine
URI: https://hdl.handle.net/20.500.11815/3580

Show full item record


Sigurðsson , M I , Kobayashi , H , Amrein , K , Nakahira , K , Rogers , A J , Pinilla-Vera , M , Baron , R M , Fredenburgh , L E , Lasky-Su , J A & Christopher , K B 2022 , ' Circulating N-formylmethionine and metabolic shift in critical illness : a multicohort metabolomics study ' , Critical Care , vol. 26 , no. 1 , 321 , pp. 321 . https://doi.org/10.1186/s13054-022-04174-y


BACKGROUND: Cell stress promotes degradation of mitochondria which release danger-associated molecular patterns that are catabolized to N-formylmethionine. We hypothesized that in critically ill adults, the response to N-formylmethionine is associated with increases in metabolomic shift-related metabolites and increases in 28-day mortality. METHODS: We performed metabolomics analyses on plasma from the 428-subject Correction of Vitamin D Deficiency in Critically Ill Patients trial (VITdAL-ICU) cohort and the 90-subject Brigham and Women's Hospital Registry of Critical Illness (RoCI) cohort. In the VITdAL-ICU cohort, we analyzed 983 metabolites at Intensive Care Unit (ICU) admission, day 3, and 7. In the RoCI cohort, we analyzed 411 metabolites at ICU admission. The association between N-formylmethionine and mortality was determined by adjusted logistic regression. The relationship between individual metabolites and N-formylmethionine abundance was assessed with false discovery rate correction via linear regression, linear mixed-effects, and Gaussian graphical models. RESULTS: Patients with the top quartile of N-formylmethionine abundance at ICU admission had a significantly higher adjusted odds of 28-day mortality in the VITdAL-ICU (OR, 2.4; 95%CI 1.5-4.0; P = 0.001) and RoCI cohorts (OR, 5.1; 95%CI 1.4-18.7; P = 0.015). Adjusted linear regression shows that with increases in N-formylmethionine abundance at ICU admission, 55 metabolites have significant differences common to both the VITdAL-ICU and RoCI cohorts. With increased N-formylmethionine abundance, both cohorts had elevations in individual short-chain acylcarnitine, branched chain amino acid, kynurenine pathway, and pentose phosphate pathway metabolites. CONCLUSIONS: The results indicate that circulating N-formylmethionine promotes a metabolic shift with heightened mortality that involves incomplete mitochondrial fatty acid oxidation, increased branched chain amino acid metabolism, and activation of the pentose phosphate pathway.


Funding Information: KN is supported by Foundation for the National Institutes of Health (NIH)/National Center for Advancing Translational Sciences grant KL2-TR-002385, R01 HL123915. AJR is supported by NIH grant R01 HL152083. LEF is supported by NIH grant R01 HL114839. RMB is supported by NIH grants R01 HL142093 and R01 GM115605. KBC is supported by NIH grant R01 GM115774. The VITdAL-ICU trial was supported by the European Society for Clinical Nutrition and Metabolism (ESPEN), a research grant including provision of study medication from Fresenius Kabi (Germany), and the Austrian National Bank (Jubiläumsfonds, Project Nr. 14143). Landspitali University Hospital Science Fund: A2021-03 Publisher Copyright: © 2022, The Author(s). © 2022. The Author(s).

Files in this item

This item appears in the following Collection(s)